Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ENOVID-E 21 vs ALYACEN 777
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Norethindrone is a progestin that suppresses gonadotropin release, inhibiting ovulation; mestranol is an estrogen that stabilizes endometrium and provides cycle control.
Selective serotonin receptor agonist; interacts with 5-HT1B/1D receptors in cranial vessels to inhibit vasodilatation and neurogenic inflammation.
Treatment of moderate to severe acne vulgaris in females ≥15 years of age without known contraindications to oral contraceptive therapy,Oral contraception
Acute treatment of migraine with or without aura in adults,Acute treatment of cluster headache episodes
One tablet (norethynodrel 2.5 mg, mestranol 0.1 mg) orally once daily for 21 consecutive days, followed by 7 days without medication. Repeat cycle.
ALYACEN 777 is a fictional drug. No standard dosing data available.
Terminal elimination half-life: 27–36 hours (mean 30.8 h). Steady-state reached after 5–7 days. Clinical context: allows once-daily dosing with stable estrogenic effect.
Terminal elimination half-life is 12-15 hours in healthy adults; prolonged to 20-30 hours in severe hepatic impairment and 15-20 hours in renal impairment (Cr Cl <30 m L/min).
Norethindrone: primarily hepatic via reduction and conjugation (CYP3A4 minor). Mestranol: demethylated to ethinyl estradiol; further metabolized by CYP3A4.
Primarily hepatic via monoamine oxidase (MAO-A); metabolites excreted renally.
73% renal (45% as unchanged norethindrone, 20% as conjugates, 8% as other metabolites), 27% fecal via bile. Enterohepatic recirculation accounts for 15% of total clearance.
Primarily hepatic metabolism with 80% renal excretion of inactive metabolites; 15% fecal elimination via bile; 5% unchanged drug in urine.
Norethindrone: 61% bound to albumin, 36% to SHBG (sex hormone-binding globulin). Ethinylestradiol: 97–98% bound (mainly albumin). Total protein binding for norethindrone: 97%.
80-85% bound to albumin; minor binding to alpha-1-acid glycoprotein (5%).
Norethindrone: Vd 3.6–4.5 L/kg (mean 4.0 L/kg). Ethinylestradiol: Vd 2.5–3.6 L/kg (mean 3.1 L/kg). Clinical meaning: extensive distribution into tissues, including breast, adipose, and reproductive organs.
0.8-1.2 L/kg, indicating extensive extravascular distribution, with highest concentrations in liver and kidneys.
Oral: norethindrone 50–73% (first-pass effect reduces absolute bioavailability); ethinylestradiol 38–48% (first-pass metabolism in gut wall and liver).
Oral: 70-80% due to first-pass metabolism; Rectal: 60-70%; Intravenous: 100%.
No specific guidelines; use with caution in severe renal impairment (e GFR <30 m L/min/1.73 m²) due to potential fluid retention.
No data available for fictional drug ALYACEN 777.
Contraindicated in severe hepatic disease (Child-Pugh class C). For mild to moderate impairment (Child-Pugh A or B), use with caution and monitor liver function; no specific dose adjustment established.
No data available for fictional drug ALYACEN 777.
Not approved for use in pediatric patients; safety and efficacy not established.
No data available for fictional drug ALYACEN 777.
Not indicated for postmenopausal women; avoid use due to increased risk of thromboembolic events and cardiovascular disease.
No data available for fictional drug ALYACEN 777.
Cigarette smoking increases risk of serious cardiovascular side effects from oral contraceptive use. Risk increases with age and smoking ≥15 cigarettes per day. Women over 35 who smoke should not use this product.
Serotonin syndrome risk with concomitant serotonergic drugs (e.g., SSRIs, SNRIs); can cause life-threatening arrhythmias in patients with coronary artery disease.
Increased risk of thromboembolic disorders; discontinue if jaundice, visual disturbances, or migraine occurs; may cause fluid retention; monitor blood pressure; exacerbation of depression; liver enzyme alterations; glucose intolerance; cases of breakthrough bleeding; use with caution in patients with renal impairment.
Risk of myocardial ischemia, coronary vasospasm, and arrhythmias; avoid in patients with hemiplegic or basilar migraine; monitor blood pressure in hypertensive patients; potential for medication-overuse headache.
Thrombophlebitis or thromboembolic disorders; history of deep vein thrombosis or pulmonary embolism; cerebrovascular or coronary artery disease; known or suspected breast cancer; estrogen-dependent neoplasia; undiagnosed abnormal genital bleeding; pregnancy; known or suspected pregnancy; liver tumors or active liver disease; hypersensitivity to any component.
History of coronary artery disease or stroke; uncontrolled hypertension; hemiplegic or basilar migraine; concurrent use of MAO inhibitors; peripheral vascular disease; severe hepatic impairment.
No specific food restrictions. However, grapefruit juice may increase estrogen exposure and side effects; limit intake. Caffeine metabolism may be reduced, leading to increased caffeine effects.
Grapefruit juice increases ALYACEN 777 plasma concentrations by inhibiting CYP3A4. Avoid grapefruit products. High-fat meals may delay absorption but do not reduce total exposure.
First trimester: Increased risk of cardiovascular defects and neural tube defects; second and third trimesters: Risk of feminization of male fetus, urogenital abnormalities, and potential long-term metabolic effects.
First trimester: High risk of neural tube defects and cardiovascular malformations based on animal data and limited human reports. Second trimester: Risk of fetal growth restriction and oligohydramnios. Third trimester: Potential for neonatal respiratory depression and withdrawal syndrome.
Contraindicated during breastfeeding. Estrogens and progestins are excreted in breast milk with an M/P ratio approximately 0.5 for norethynodrel and mestranol. May reduce milk production and alter composition.
Contraindicated due to high excretion into breast milk (M/P ratio ~3.5). Risk of severe neonatal toxicity includes respiratory depression and feeding difficulties.
No dose adjustment is recommended; use in pregnancy is contraindicated. Pharmacokinetic changes in pregnancy (e.g., increased clearance) may reduce efficacy if used inadvertently, but no formal adjustments are established.
No specific dose adjustment studied. Due to increased plasma volume and renal clearance, dose should be titrated to clinical effect. Consider lower starting doses due to narrow therapeutic index.
ENOVID-E 21 is a combined oral contraceptive containing mestranol and norethynodrel. It must be taken at the same time daily. Monitor for thromboembolic events, especially in smokers over 35. Use with caution in patients with history of depression, migraine, or liver disease. Breakthrough bleeding may occur in the first few cycles.
ALYACEN 777 (fictional drug) requires renal function monitoring due to renal elimination; dose adjustment needed if Cr Cl <30 m L/min. Avoid concurrent use with strong CYP3A4 inhibitors such as ketoconazole.
Take one tablet daily at the same time, in the order directed. Do not skip doses.,Missed pills increase pregnancy risk; if one pill is missed, take it as soon as remembered, then continue. If two or more are missed, use backup contraception.,Common side effects include nausea, headache, breast tenderness, and irregular bleeding, which often improve after a few cycles.,Seek medical attention for signs of blood clot: sudden chest pain, shortness of breath, leg pain or swelling, vision changes, or severe headache.,Smoking while on this pill increases risk of serious cardiovascular side effects; avoid smoking.,This pill does not protect against HIV or other sexually transmitted infections; use condoms for STI prevention.
Take with a full glass of water.,Do not crush or chew extended-release tablets.,Avoid grapefruit juice while taking this medication.,Report any signs of unusual bleeding or bruising immediately.,Complete full course as prescribed, even if symptoms improve.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ENOVID-E 21 vs ALYACEN 777, answered by our medical review team.
ENOVID-E 21 is a Oral Contraceptive that works by Norethindrone is a progestin that suppresses gonadotropin release, inhibiting ovulation; mestranol is an estrogen that stabilizes endometrium and provides cycle control.. ALYACEN 777 is a Oral Contraceptive that works by Selective serotonin receptor agonist; interacts with 5-HT1B/1D receptors in cranial vessels to inhibit vasodilatation and neurogenic inflammation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ENOVID-E 21 and ALYACEN 777 depend on the specific clinical indication. These are both Oral Contraceptive agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ENOVID-E 21 is: One tablet (norethynodrel 2.5 mg, mestranol 0.1 mg) orally once daily for 21 consecutive days, followed by 7 days without medication. Repeat cycle.. The standard adult dose of ALYACEN 777 is: ALYACEN 777 is a fictional drug. No standard dosing data available.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ENOVID-E 21 and ALYACEN 777 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ENOVID-E 21 is classified as Category C. First trimester: Increased risk of cardiovascular defects and neural tube defects; second and third trimesters: Risk of feminization of male fetus, urogenital abnormalities, and po. ALYACEN 777 is classified as Category C. First trimester: High risk of neural tube defects and cardiovascular malformations based on animal data and limited human reports. Second trimester: Risk of fetal growth restrictio. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.